Clinical Pipeline

ProductIndicationStatus
REZUROCK
(belumosudil)
(Selective ROCK2 inhibitor)
Chronic
Graft-Versus-Host
Disease (cGVHD)
  • FDA approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systematic therapy
Systemic Sclerosis
  • Open-label Phase 2 clinical trial ongoing; initial data expected YE 2021
  • Phase 2 placebo-controlled clinical trial ongoing
KD033
(anti-PD-L1/IL-15 fusion protein)
Immuno-oncology
  • Phase 1 clinical trial ongoing

Learn More